Ventilator associated pneumonia in COVID-19 patients: A retrospective cohort study

FERLİÇOLAK L., SARICAOĞLU E. M., BİLBAY B., ALTINTAŞ N. D., YÖRÜK F.

TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, cilt.71, sa.1, ss.41-47, 2023 (ESCI) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 71 Sayı: 1
  • Basım Tarihi: 2023
  • Doi Numarası: 10.5578/tt.20239906
  • Dergi Adı: TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, CAB Abstracts, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.41-47
  • Anahtar Kelimeler: Acinetobacter spp, COVID-19, intensive care unit, mortality, ventilator associated pneumonia
  • Ankara Üniversitesi Adresli: Evet

Özet

Ventilator associated pneumonia in COVID-19 patients: A retrospective cohort studyIntroduction: We aimed to evaluate ventilator-associated pneumonia (VAP) incidence rate, risk factors, and isolated microorganisms in COVID-19 patients as the primary endpoint. Evaluation of VAP-associated intensive care unit (ICU) and hospital mortalities was the secondary endpoint.Materials and Methods: Records of patients admitted between March 2020 -June 2021 to our pandemic ICU were reviewed and COVID-19 patients with VAP and non-VAP were evaluated retrospectively. Comorbidities, manage-ment, length of ICU stay, and outcomes of VAP and non-VAP patients, as well as risk factors for VAP mortality, were identified.Results: During the study period, 254 patients were admitted to the ICU. After the exclusion, the data of 208 patients were reviewed. In total, 121 patients required invasive mechanical ventilation, with 78 (64.5%) developing VAP. Length of ICU and hospital stays were longer in VAP patients (p< 0.01 and p< 0.01 respectively). Steroid use was higher in VAP patients, although it was not statistically significant (p= 0.06). APACHE II score (p< 0.01) was higher in non-VAP patients. ICU mortality was high in both groups (VAP 70%, non-VAP 77%). VAP mortality was higher in males (p= 0.03) and in patients who requ-ired renal replacement therapy (p= 0.01). Length of ICU stay (p= 0.04), and length of hospital stay (p< 0.01) were both high in VAP survivors. The most common isolated microorganisms were Acinetobacter spp. and Klebsiella spp. in VAP patients and most of them were extensively drug-resistant.Conclusion: Critically ill COVID-19 patients who required invasive mechani-cal ventilation developed VAP frequently. The length of ICU stay was longer in patients who developed VAP and ICU mortality was high in both VAP and non-VAP patients. The length of hospital and ICU stays among VAP survivors were also considerably high which is probably related to the long recovery period of COVID-19. The most frequently isolated microorganisms were Acinetobacter spp. and Klebsiella spp. in VAP patients.